

ADOA PROGRAM: INITIATION OF GLOBAL REPEAT DOSE STUDY

- **PYC is progressing an investigational drug candidate (known as PYC-001) that addresses the underlying cause of a blinding eye disease called Autosomal Dominant Optic Atrophy (ADOA) through clinical trials**
- **The Company today announces that it has initiated a global repeat dose study of PYC-001 in patients with ADOA (known as the MYRTLE study) and that the first subject in this clinical trial has now received their initial dose of PYC-001**
- **The objective of the MYRTLE study is to evaluate the safety/tolerability and efficacy profile of repeat dosing of PYC-001 in the ADOA population with a view to establishing clinical proof of concept for the drug candidate prior to initiation of a registrational study**
- **Data from the Myrtle study across both safety/tolerability and efficacy endpoints is expected to be available in H2 2026¹**

PERTH, Australia and SAN FRANCISCO, California – 21 October 2025

PYC Therapeutics Limited (ASX:PYC) (**PYC** or the **Company**) is a precision medicine Company dedicated to changing the lives of patients with genetic diseases who have no treatment options available.


The Company currently has three clinical-stage drug development programs including a drug candidate (known as PYC-001) that addresses the underlying cause of Autosomal Dominant Optic Atrophy (ADOA). ADOA affects 1 in every 35,000² people and there are currently no approved treatment options available for patients with ADOA.

PYC today announces that it has initiated a global repeat dose Phase 1b study of PYC-001 in patients with ADOA (See Figure 1 for the proposed clinical development pathway for PYC-001 in ADOA).

¹ Subject to the risks and uncertainties set out in the Company's securities exchange disclosures of 17 February 2025


² Yu-Wai-Man, P. et al. The Prevalence and Natural History of Dominant Optic Atrophy Due to OPA1 Mutations Ophthalmology. 2010;117(8):1538-46 doi: 10.1016/j.ophtha.2009.12.038

Figure 1. Proposed clinical development pathway for PYC-001



The first ADOA patient enrolled in this clinical trial has now received their initial dose of PYC-001 in their study eye via intravitreal administration. Each patient enrolled in the study is expected to receive 3 doses of PYC-001 in a single eye³. The study will evaluate three different doses of PYC-001 (10, 30 and 60 micrograms per eye) and two different dose intervals (8 and 12-week dosing intervals) (See Figure 2 for a detailed overview of the MYRTLE study protocol).

Figure 2. Phase 1b study overview for PYC-001



³ With the exception of subjects enrolled in the 60 microgram cohort who will receive one dose under a single dose study protocol and a further three doses if rolling over into the repeat dose protocol

Study Details

Details of this repeat dose study include:

- **10 and 30 microgram repeat dose cohorts:** 3 patients will be enrolled in each of 4 repeat dose cohorts:
 - Two cohorts of 10 microgram repeat doses (8- and 12-week intervals)
 - Two cohorts of 30 microgram repeat doses (8- and 12-week intervals)
- **60 microgram single and repeat dose cohorts:** 3 treatment naïve patients will be dosed with a single 60 microgram dose. The Safety Review Committee (SRC) overseeing this clinical trial will meet following 4-week follow-up data from all patients in this cohort to enable progression to two 60 microgram repeat dose cohorts (8- and 12-week intervals).
- **Primary objectives:** to evaluate the safety/tolerability profile and to determine the optimal dose and dosing regimen for PYC-001.
- **Secondary objectives:** to provide preliminary efficacy insights following administration of the drug candidate
- **Read-outs:** The study treatment period is projected to end in Q4 2026

Next Steps

This Phase 1b study will be followed by an Open-Label Extension (OLE) study of PYC-001⁴. Both the Phase 1b and OLE studies are intended to establish clinical proof-of-concept for PYC-001 in the ADOA population prior to progression into a global registrational trial (expected to commence in 2027) directed towards supporting a New Drug Application for PYC-001 in ADOA.

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – the indications with the highest likelihood of success in clinical development⁵.

For more information, visit pyctx.com, or follow us on [LinkedIn](#).

⁴ Subject to successful completion of this study and the risks and uncertainties outlined in the Company's ASX disclosures of 17 February 2025

⁵ Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank
<https://doi.org/10.1101/2020.11.02.2022232>

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations, and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations, and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited.

CONTACT US

Investor relations and media contact

investor@pyctx.com

